bluebird bio Q4 EPS Estimate Increased by Leerink Partnrs

bluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Stock analysts at Leerink Partnrs lifted their Q4 2024 earnings estimates for bluebird bio in a research report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings of ($4.42) per share for the quarter, up from their prior estimate of ($4.47). The consensus estimate for bluebird bio's current full-year earnings is ($27.17) per share. Leerink Partnrs also issued estimates for bluebird bio's FY2025 earnings at ($6.42) EPS.

Other equities research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. cut bluebird bio from a "neutral" rating to an "underweight" rating in a research note on Friday, November 15th. Barclays raised their price target on shares of bluebird bio from $2.00 to $40.00 and gave the company an "overweight" rating in a report on Tuesday, December 31st. StockNews.com started coverage on bluebird bio in a report on Friday, December 20th. They set a "sell" rating on the stock. Bank of America lowered bluebird bio from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $60.00 to $10.00 in a report on Friday, November 15th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and set a $80.00 price target on shares of bluebird bio in a report on Friday, November 15th. Three analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $49.14.

bluebird bio Stock Down 0.9 %

Shares of NASDAQ:BLUE traded down $0.07 during midday trading on Friday, hitting $7.80. 177,656 shares of the stock were exchanged, compared to its average volume of 196,474. The business's fifty day simple moving average is $8.17 and its two-hundred day simple moving average is $11.86. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. bluebird bio has a 52-week low of $5.80 and a 52-week high of $38.40. The company has a market capitalization of $75.82 million, a PE ratio of -0.21 and a beta of 0.68.

Hedge Funds Weigh In On bluebird bio

Large investors have recently made changes to their positions in the company. Rhumbline Advisers boosted its stake in shares of bluebird bio by 25.4% in the 2nd quarter. Rhumbline Advisers now owns 292,436 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 59,219 shares during the last quarter. AQR Capital Management LLC boosted its stake in bluebird bio by 315.3% in the second quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company's stock valued at $1,223,000 after acquiring an additional 1,013,144 shares during the last quarter. SG Americas Securities LLC raised its position in shares of bluebird bio by 152.4% during the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company's stock valued at $64,000 after acquiring an additional 74,185 shares during the last quarter. FMR LLC lifted its stake in shares of bluebird bio by 8.1% in the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company's stock valued at $1,289,000 after purchasing an additional 186,903 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in shares of bluebird bio by 2,270.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company's stock worth $193,000 after purchasing an additional 355,562 shares during the last quarter. Institutional investors and hedge funds own 87.43% of the company's stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.